Want to see CH:EVE full AI Analyst Report?
EVE Stock Chart & Stats
CHF2.32
-CHF0.13(-5.80%)
At close: 4:00 PM EDT
CHF2.32
-CHF0.13(-5.80%)
Day’s Range― - ―
52-Week RangeCHF0.75 - CHF2.74
Previous CloseN/A
Volume1.72K
Average Volume (3M)38.59K
Market Cap
CHF14.64M
Enterprise ValueCHF0.23
Total Cash (Recent Filing)CHF5.61M
Total Debt (Recent Filing)CHF0.00
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Feb 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding7,230,626
10 Day Avg. Volume23,020
30 Day Avg. Volume38,591
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.5
Revenue Forecast (FY)CHF60.90M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageThe absence of reported debt reduces interest burden and refinancing exposure, giving Evolva greater financial flexibility than a highly leveraged peer. This balance-sheet resilience can help preserve strategic options while the company addresses its weak operating performance.
Reduced Cash BurnA meaningful reduction in cash burn improves the company’s operating runway and may slow the pace at which capital is consumed. Although cash flow remains negative, continued discipline could support restructuring, development, or commercialization efforts over coming quarters.
Biotechnology And IP PlatformEvolva’s biotechnology, fermentation, ingredient, and licensing capabilities provide a platform for creating and monetizing differentiated specialty products. If successfully commercialized, intellectual property and formulation know-how could support scalable partnerships beyond a single product.
Bears Say
Zero Operating RevenueThe absence of reported revenue indicates that Evolva currently lacks operating scale and does not have a demonstrated commercial base supporting ongoing activities. This weakens visibility into future growth, limits internal funding capacity, and raises the challenge of rebuilding customer and product traction.
Persistent Negative Cash FlowConsistently negative operating and free cash flow show that the business has not reached self-funding operations across the reported period. Continued cash consumption can constrain investment, increase reliance on financing or asset reductions, and make durable execution more difficult.
Shrinking Capital Base And Unstable ProfitabilityDeclining equity and assets point to erosion of the resources available to support the business, while sharply changing returns and earnings indicate limited profit consistency. The 2024 improvement therefore has not yet demonstrated a durable turnaround in shareholder value creation.
Evolva Holding News
EVE FAQ
What was Evolva Holding’s price range in the past 12 months?
Evolva Holding lowest stock price was CHF0.75 and its highest was CHF2.74 in the past 12 months.
What is Evolva Holding’s market cap?
Evolva Holding’s market cap is CHF14.64M.
When is Evolva Holding’s upcoming earnings report date?
Evolva Holding’s upcoming earnings report date is Feb 19, 2027 which is in 153 days.
How were Evolva Holding’s earnings last quarter?
Evolva Holding released its earnings results on Apr 29, 2026. The company reported -CHF0.04 earnings per share for the quarter.
Is Evolva Holding overvalued?
According to Wall Street analysts Evolva Holding’s price is currently Overvalued.
Does Evolva Holding pay dividends?
Evolva Holding does not currently pay dividends.
What is Evolva Holding’s EPS estimate?
Evolva Holding’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evolva Holding have?
Evolva Holding has 7,230,626 shares outstanding.
What happened to Evolva Holding’s price movement after its last earnings report?
Evolva Holding reported an EPS of -CHF0.04 in its last earnings report. Following the earnings report the stock price went up 3.017%.
Which hedge fund is a major shareholder of Evolva Holding?
Currently, no hedge funds are holding shares in CH:EVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evolva Holding
EvoNext Holdings SA is dedicated to the exploration, creation, and distribution of pioneering ingredients across the nutritional, health, and wellness domains. Founded in 2004, the company's inception is attributed to Alexandra Santana Sørensen, Søren V. S. Nielsen, and Neil Goldsmith. Its corporate headquarters are located in Reinach, Switzerland.
Technical Analysis
Molecular Partners AG
―
Lonza Group Ltd
―
Bachem Holding AG
―
Kuros Biosciences
―
Xlife Sciences Ltd.
―